Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

Presentation ACC 2025

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Presenter: Marc P. Bonaca

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

Presentation ACC 2024

Comparison of IVUS-guided vs. Angiography-guided Angioplasty for the Outcomes of DCB in the Treatment of Femoropopliteal Artery Disease

Presenter: Young-Guk Ko

April 08, 2024

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

L.A. McKeown

May 21, 2021

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Conference News ACC 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

Yael L. Maxwell

March 31, 2020

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Conference News ACC 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Michael O'Riordan

April 01, 2019

Presentation ACC 2018

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Presenter: Mehdi H. Shishehbor

March 12, 2018

Advertisement

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

What’s Going to Be Hot at ACC 2025?

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Comparison of IVUS-guided vs. Angiography-guided Angioplasty for the Outcomes of DCB in the Treatment of Femoropopliteal Artery Disease

What’s Going to Be Hot at ACC/WCC 2023?

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content